← Back to Search

Other

VIP236 for Advanced Cancer

Phase 1
Recruiting
Research Sponsored by Vincerx Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests a new drug to see if it's safe and effective for treating advanced solid tumor cancer.

Who is the study for?
This trial is for adults over 18 with advanced solid tumors that have not responded to standard treatments. Participants must be able to consent, follow study procedures, and have a performance status showing they can carry out daily activities. They need proper bone marrow, liver, and kidney function.
What is being tested?
The trial is testing VIP236 as a solo treatment given through the vein (IV) to find the highest dose patients can take without severe side effects. It's for those with advanced cancer who've tried all other options or can't use them.
What are the potential side effects?
While specific side effects of VIP236 are not listed here, common ones in such trials include reactions at the infusion site, fatigue, nausea, changes in blood counts affecting immunity and clotting risk, liver or kidney issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose Escalation of VIP236Experimental Treatment1 Intervention
Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer

Find a Location

Who is running the clinical trial?

Vincerx Pharma, Inc.Lead Sponsor
3 Previous Clinical Trials
152 Total Patients Enrolled
Vincerx Study DirectorStudy DirectorVincerx Pharma, Inc.
3 Previous Clinical Trials
152 Total Patients Enrolled

Media Library

VIP236 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05712889 — Phase 1
Tumors Research Study Groups: Dose Escalation of VIP236
Tumors Clinical Trial 2023: VIP236 Highlights & Side Effects. Trial Name: NCT05712889 — Phase 1
VIP236 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05712889 — Phase 1
~9 spots leftby Sep 2025